Highest-materiality recent filing
ImmunityBio Q2 net product revenue $50.7M, up 92% YoY; eighth consecutive quarter of growth
Net product revenue $50.7M in Q2 2026, up 92% YoY and 15% sequentially; first-half revenue $94.8M, up 121% YoY.
ImmunityBio gets UAE marketing authorization for ANKTIVA in bladder and lung cancers
UAE approved ANKTIVA for BCG-unresponsive NMIBC (CIS and papillary) and metastatic NSCLC after checkpoint failure.
ImmunityBio signs exclusive U.S. supply agreement with Japan BCG Laboratory for Tokyo strain of BCG
Agreement grants ImmunityBio exclusive U.S. rights to develop and commercialize Tokyo-172 BCG for 10 years after FDA approval.
ImmunityBio Q1 net product revenue $44.2M, up 168% YoY; ANKTIVA approvals expand; cash $381M
Q1 2026 net product revenue $44.2M, up 168% YoY ($16.5M) and 15% sequentially from Q4 2025 ($38.3M).
ImmunityBio reports preliminary Q1 2026 net product revenue $44.2M, up 168% YoY, cash $381M
Preliminary Q1 2026 net product revenue ~$44.2M, up 168% YoY and 15% sequentially from $38.3M in Q4 2025.
ImmunityBio submits response to FDA OPDP Warning Letter; outlines corrective actions
Submitted comprehensive response to FDA OPDP Warning Letter dated March 13, 2026.
ImmunityBio secures $75M non-dilutive RIPA financing; $25M note conversion reduces debt
Additional $75M under Revenue Interest Purchase Agreement (RIPA) with Oberland Capital; total committed capital $375M.
ImmunityBio reports 700% YoY revenue growth to $113M; first lung cancer approval in Saudi Arabia
Full-year 2025 ANKTIVA net product revenue $113M (up ~700% YoY); Q4 net revenue $38.3M (up 431% YoY).
ImmunityBio gets EC approval for ANKTIVA+BCG in NMIBC CIS; now authorized in 33 countries
EC conditional marketing authorization for ANKTIVA+BCG in BCG-unresponsive NMIBC CIS; 71% complete response rate, median DOR 26.6 months.
ImmunityBio amends $505M convertible note to allow partial conversion at any time
Convertible note amendment allows holder Nant Capital to convert any portion of $505M principal into common stock at any time before maturity.
Preliminary FY2025 net product revenue ~$113.0M, ~700% YoY increase; Q4 2025 revenue ~$38.3M, up 20% QoQ and 431% YoY.
Saudi FDA grants accelerated approval for ImmunityBio's ANKTIVA in NSCLC and NMIBC
SFDA approved ANKTIVA + checkpoint inhibitor for metastatic NSCLC after standard-of-care failure; first worldwide approval for this subcutaneous IL-15 agonist.
ImmunityBio expands ATM equity offering capacity by $460M; authorized shares increased by 300M
Amendment to ATM agreement with Jefferies LLC authorizes up to $459.97M in additional common stock sales.
ImmunityBio receives EMA positive opinion for ANKTIVA+BCG in NMIBC CIS in Europe
EMA recommends conditional marketing authorization for ANKTIVA+BCG to treat BCG-unresponsive NMIBC with CIS.
ImmunityBio Q3 product revenue up 434% YoY to $31.8M; net loss narrows to $67.3M
Product revenue $31.8M in Q3 2025 vs $6.0M in Q3 2024; YTD sales $74.7M (+434%).
ImmunityBio reaches preliminary settlement in shareholder derivative lawsuit
Court preliminarily approved derivative settlement on July 29, 2025, with final hearing set for Nov 4, 2025.
ImmunityBio Q2 revenue jumps 60% to $26.4M; net loss narrows to $92.6M
Q2 product revenue $26.4M, up 60% from Q1 and from $990k in Q2 2024; YTD sales $42.9M.
ImmunityBio raises $80M equity; Q2 revenue $26.4M (+60% QoQ), ANKTIVA units up 246%
Registered direct offering of 29.6M shares and warrants at $2.70/unit, gross proceeds ~$80M.
ImmunityBio Reports Q1 2025 Net Product Revenue of $16.5M, Up 129% from Q4 2024
Net product revenue for Q1 2025 reached $16.5 million, a 129% increase over $7.2 million in Q4 2024.
ImmunityBio receives FDA refusal to file for ANKTIVA sBLA in NMIBC papillary indication
FDA issued Refusal to File (RTF) letter on May 2, 2025 for sBLA of ANKTIVA+BCG in BCG-unresponsive papillary NMIBC.
ImmunityBio Q1 net product revenue ~$16.5M (+129% QoQ); submits sBLA for NMIBC papillary disease
Q1 2025 net product revenue ~$16.5M (+129% QoQ from $7.2M in Q4 2024).
ImmunityBio raises $75M in registered direct offering of common stock and warrants
Gross proceeds of ~$75M from sale of 29.0M shares and warrants; warrants exercisable at $3.101 for 5 years.
ImmunityBio Q4 net product revenue $7.2M; Feb ANKTIVA units up 67% MoM; RMAT designation granted
Net product revenue $7.2M in Q4 2024, up 21% QoQ from $6.0M in Q3; full-year net product revenue $14.2M.
ImmunityBio prices $100M public offering at $3/sh and restructures $505M Nant Capital note
Public offering of 33.3M shares at $3/sh for gross proceeds ~$100M; net to company ~$93.1M from firm shares.
ImmunityBio announces public offering and $505M debt restructuring with Nant Capital
Proposed public offering of common stock; Jefferies & Piper Sandler lead; 30-day option for 15% additional shares.
100 patients with BCG-unresponsive NMIBC CIS enrolled; 71% achieved complete response (CR) rate.
ImmunityBio Q3 product revenue $6.0M, net loss narrows; ANKTIVA J-code set for Jan 2025
Net product revenue of $6.0M from ANKTIVA launch in Q3, up from $1.0M in Q2; diluted EPS -$0.14 vs -$0.19 YoY.
ImmunityBio settles IP lawsuit with HCW, acquires TGFb trap assets and licenses
Settlement resolves arbitration and federal lawsuit with HCW Biologics; no monetary consideration from ImmunityBio.
ImmunityBio gets FDA approval for ANKTIVA in BCG-unresponsive NMIBC; CR rate 62%, DOR >47 months
FDA approved ANKTIVA (N-803) plus BCG for BCG-unresponsive NMIBC with CIS on April 22, 2024.
$200M non-dilutive royalty financing closed; additional $100M contingent on FDA approval of Anktiva for NMIBC (PDUFA Apr 23, 2024).
ImmunityBio restructures $470M in debt; gets $200M new capital from founder
Issued $200M convertible note to Nant Capital (founder affiliate) with 3-yr term, convertible at 50% premium to market price.
ImmunityBio subsidiary to enforce settlement as Sorrento fails to pay judgments
Sorrento failed to pay judgments held by NantCell and NANTibody by August 31, 2023 deadline.
Bankruptcy court approves Sorrento settlement; two scenarios could resolve ImmunityBio litigation
Bankruptcy court approved settlement on Aug 14, 2023 between ImmunityBio and Sorrento (Case No. 23-90085).
ImmunityBio closes $40M registered direct offering of common stock and warrants
Issued 14,569,296 shares at $2.7455 per share with warrants for 14,569,296 shares at $3.2946.
ImmunityBio updates Sorrento settlement terms; securities class action filed
Sorrento settlement hearing set for Aug 14, 2023; two scenarios: pay judgments by Aug 31 or release claims and relinquish NANTibody interests.
ImmunityBio signs $30M promissory note with Nant Capital (SOFR+8%, due Dec 31, 2023)
Three $10M advances available; interest at Term SOFR + 8% per annum payable quarterly.
FDA rejects ImmunityBio's BLA for Anktiva (N-803) in bladder cancer; CRL cites manufacturing issues
FDA issued Complete Response Letter for Anktiva (N-803) + BCG in BCG-unresponsive NMIBC with CIS.
BLA for N-803+BCG in BCG-unresponsive NMIBC with CIS; PDUFA date May 23, 2023; approval uncertain.
Gross proceeds of ~$50M from sale of 14,072,615 shares and warrants; warrants could yield up to $60M more if fully exercised.
LA County Superior Court confirms $176.37M arbitration award against Sorrento; $159.42M payable to ImmunityBio subsidiary NantCell.
On February 7, 2025, John Owen Brennan notified the Secretary of ImmunityBio, Inc., a Delaware corporation (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and from all committees of the Board on which he served, effective as of February 7, 2025.
appointed Patrick Soon-Shiong, M.D., as Global Chief Scientific and Medical Officer of the Company, a newly created executive position, effective immediately.
Max materiality 0.90 · Median 0.75 · Most common event other_material